CRDF FY 2024 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$683,000+40.0% YoY

Gross Profit

$683,000100.0% margin

Operating Income

-$49M-7123.1% margin

Net Income

-$45M-6651.7% margin

EPS (Diluted)

$-0.95

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$97M

Total Liabilities

$14M

Stockholders' Equity

$83M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$683,000	$488,000	+40.0%
Gross Profit	$683,000	$488,000	+40.0%
Operating Income	-$49M	-$45M	-7.1%
Net Income	-$45M	-$41M	-9.6%